New hope in fight against deadly brain cancer: testing a powerful Immune-Boosting drug
NCT ID NCT03174197
Summary
This study tested whether adding a new immunotherapy drug (atezolizumab) to the standard treatment of chemotherapy and radiation could help patients with newly diagnosed glioblastoma, a very aggressive brain cancer. The goal was to see if this combination was safe and if it could help patients live longer by helping the immune system attack the cancer. The trial involved 60 patients who had recently had surgery for their brain tumor.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.